We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+2.6%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$3.34B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
4.72%
Top 10 Hldgs %
12.01%
Holding
1,564
New
189
Increased
576
Reduced
529
Closed
163

Sector Composition

Rank Sector Weight
1 Energy 11.94%
2 Healthcare 10.62%
3 Industrials 9.8%
4 Technology 9.43%
5 Financials 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WBD icon
276
Warner Bros
WBD
$63.9B
$2.96M 0.09%
70,031
-261
-0.4% -$11K
BVN icon
277
Compañía de Minas Buenaventura
BVN
$8.09B
$2.94M 0.09%
234,030
+7,919
+4% +$99.1K
TWX
278
DELISTED
Time Warner Inc
TWX
$2.94M 0.09%
46,871
-1,729
-4% -$109K
PFF icon
279
iShares Preferred and Income Securities ETF
PFF
$13.3B
$2.92M 0.09%
74,929
+20,025
+36% +$765K
GSK icon
280
GSK
GSK
$104B
$2.9M 0.09%
43,397
-1,888
-4% -$128K
XLE icon
281
State Street Energy Select Sector SPDR ETF
XLE
$39.2B
$2.9M 0.09%
65,044
+14,356
+28% +$619K
GTAT
282
DELISTED
GT ADVANCED TECHNOLOGIES INC COM STK (DE)
GTAT
$2.89M 0.09%
169,713
+60,313
+55% +$777K
BNDX icon
283
Vanguard Total International Bond ETF
BNDX
$82.1B
$2.89M 0.09%
+57,076
New +$2.87M
TYY
284
DELISTED
TORTOISE ENERGY CAPITAL CORP
TYY
$2.89M 0.09%
87,046
+3,919
+5% +$127K
MMP
285
DELISTED
Magellan Midstream Partners, L.P.
MMP
$2.85M 0.09%
40,900
-2,486
-6% -$165K
REGN icon
286
Regeneron Pharmaceuticals
REGN
$77.4B
$2.84M 0.09%
9,469
-249
-3% -$76.7K
PCY icon
287
Invesco Emerging Markets Sovereign Debt ETF
PCY
$1.38B
$2.83M 0.08%
100,878
+506
+0.5% +$13.8K
DHR icon
288
Danaher
DHR
$138B
$2.81M 0.08%
55,794
-619
-1% -$31.5K
ES icon
289
Eversource Energy
ES
$27.8B
$2.79M 0.08%
61,307
-2,126
-3% -$92.8K
MSEX icon
290
Middlesex Water
MSEX
$1.04B
$2.79M 0.08%
127,841
+13,299
+12% +$273K
EMR icon
291
Emerson Electric
EMR
$83.3B
$2.74M 0.08%
41,057
-3,024
-7% -$199K
DDD icon
292
3D Systems Corp
DDD
$441M
$2.73M 0.08%
46,089
-30,139
-40% -$2.25M
HCA icon
293
HCA Healthcare
HCA
$85.7B
$2.72M 0.08%
51,856
-824
-2% -$41K
IWO icon
294
iShares Russell 2000 Growth ETF
IWO
$14.4B
$2.71M 0.08%
19,886
-37,863
-66% -$5.18M
AZO icon
295
AutoZone
AZO
$49.1B
$2.7M 0.08%
5,020
MTRX icon
296
Matrix Service
MTRX
$320M
$2.68M 0.08%
79,450
-14,550
-15% -$436K
O icon
297
Realty Income
O
$60.1B
$2.67M 0.08%
67,528
-404
-0.6% -$16K
SDLP
298
DELISTED
SEADRILL PARTNERS LLC
SDLP
$2.67M 0.08%
8,907
+3,602
+68% +$1.12M
VGK icon
299
Vanguard FTSE Europe ETF
VGK
$30.8B
$2.67M 0.08%
45,275
-24,846
-35% -$1.45M
URS
300
DELISTED
URS CORP
URS
$2.67M 0.08%
56,697
-6,259
-10% -$303K

Similar funds

Oppenheimer & Co's Q1 2014 Portfolio in Review

As of Q1 2014, Oppenheimer & Co held 1,564 positions worth $3.34B, up 6.7% from $3.13B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Oppenheimer & Co deployed $157M of net new capital in Q1 2014, opening 189 new positions and adding to 576 existing holdings. Its largest new stake was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.

By sector, the portfolio is most concentrated in Energy at 12% of assets, down from 12% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Vanguard Dividend Appreciation ETF, an estimated $7.79M trimmed.

  • Oppenheimer & Co's largest Q1 2014 buy was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.
  • Oppenheimer & Co added most to Monsanto Co in Q1 2014, an estimated $30M increase.
  • Oppenheimer & Co's biggest Q1 2014 reduction was Vanguard Dividend Appreciation ETF, cutting an estimated $7.79M.
  • Oppenheimer & Co fully exited TetraLogic Pharmaceuticals Corporation in Q1 2014, selling an estimated $10.2M.
  • Oppenheimer & Co's ten largest holdings make up 12% of its $3.34B portfolio in Q1 2014.
  • Oppenheimer & Co opened 189 new positions and closed 163 in Q1 2014.
  • Oppenheimer & Co's portfolio value rose 6.7% quarter-over-quarter to $3.34B.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.